56 results about "Benzoates" patented technology

A method of synthesizing the benzoate salt of 5-MeO-DMT comprising the step of treating the hydrochloride salt of 5-MeO-DMT with a base, prior to the addition of benzoic acid.

A method of synthesizing the benzoate salt of 5-MeO-DMT comprising the step of treating the hydrochloride salt of 5-MeO-DMT with a base, prior to the addition of benzoic acid.

The invention relates to the technical field of synthesis of organic compounds, and discloses a preparation method of N-Boc-cis-4-hydroxy-L-proline methyl ester, which comprises the following steps: step 1, synthesis of (2S, 4R)-4-p-toluenesulfonyloxy-1, 2-pyrroline dicarboxylic acid-1-tert-butyl ester-2-methyl ester (2): (2S, 4R)-4-hydroxy-1, 2, 4-triazole-2-methyl ester (3) is prepared from (2S, 4R)-4-hydroxy-1, 2, 4-triazole-2-methyl ester and (2S, 4R)-4-p-toluenesulfonyloxy-1, 2-pyrroline dicarboxylic acid-1- The preparation method comprises the following steps: dissolving 1-tert-butyl-2-methyl 2-pyrroline dicarboxylic acid-1-tert-butyl ester-2-methyl ester in dichloromethane; according to the method, (2S, 4R)-4-hydroxy-1, 2-pyrroline dicarboxylic acid-1-tert-butyl-2-methyl ester which is cheap and easy to obtain in the market is adopted as a raw material, after p-benzoylation and acetylation are performed, hydroxyl of the raw material is converted from trans form to cis form, chiral conversion is performed, and finally the target product is synthesized. The used acetate replaces benzoate, the raw materials are cheaper, and the generated by-product acetic acid is more environment-friendly than benzoic acid, so that the method is suitable for large-scale production.

A quinazoline derivative (represented by the formula (I)) salt's crystal form, a preparation method and application are provided; specifically, the hydrochloride crystal form A, B, C, D, F, H, I, Sulphate crystal form A, Maleate crystal form A, Succinate crystal form A, Adipate crystal form A, Glycolate crystal form A, Malate crystal form A, Fumarate Salt crystal form A, besylate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A of the quinazoline derivative represented by formula (I). The salt crystal form provided by the present invention has good stability, which can be used in the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability, which is of great significance for further research on the efficacy of such solid drugs.

A method for making the benzoate salt of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]-2-fluoro-benzonitrile, designated compound (A), and methods for using compound (A) are provided.

To provide a pharmaceutical composition for preventing or treating cognitive dysfunction.SOLUTION: The pharmaceutical composition contains benzoic acid or a benzoic acid salt.SELECTED DRAWING: None

The invention discloses a preparation method of a high-quality perovskite thick film for an X-ray detector, and relates to the technical field of radiation detection materials and devices. The preparation method of the thick film comprises the following steps: preparing a precursor solution from lead iodide, cesium iodide, formamidine iodide, methylamine iodide, 4-guanidinobenzoic acid hydrochloride, N, N-dimethylformamide and acetonitrile; a bulk phase functional additive is introduced to optimize a large number of Schottky defects at the grain boundary of the perovskite thick film; depositing onto a heated conductive glass substrate using a spray coating technique; and in combination with a low-temperature solvent atmosphere annealing process, secondary growth of crystal grains and grain boundary healing are promoted, and a large-area polycrystalline thick film can be obtained.

Solid forms of compound of (2R)-1-[4-[(R)-amino(5-chloro-2-hydroxy-4-methylphenyl)methyl]piperidin-1-yl]-2,3-dihydroxypropan-1-one are described. The solid form may be a pharmaceutically acceptable salt of the compound. The salt may be a carboxylic acid salt, such as a benzoic acid salt, a cinnamic acid salt, or a glutaric acid salt. Pharmaceutical compositions comprising the same and method of using the same in treating a condition such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, atopic dermatitis, and alopecia areata are also described.

A method for reducing fouling in a styrene production process, the method comprising the steps of introducing an additive into a stream containing styrene and a byproduct, divinylbenzene (DVB), wherein the additive comprises at least one compound comprising one or more functional groups selected from the group consisting of amines, alcohols, aminoalcohols, labile C-C, esters, carbamates, aldehydes, ketones, acids, acetates, benzoates, labile hydrogen, and combinations thereof, and having a boiling point greater than or equal to 170°C and within ±10°C, ±20°C, ±30°C, ±40°C, ±50°C, or ±60°C of the boiling point of divinylbenzene (DVB), which is 195°C, wherein the at least one compound is effective in inhibiting crosslinking of the divinylbenzene (DVB). A system for performing the method is also provided.

The present invention relates to aqueous liquid detergent compositions, wherein the compositions exhibit a high microbial stability without the use of conventional preservatives. The liquid detergent composition of the invention is particularly useful for washing laundry, where a good cleaning performance is needed and where the consumer takes into account the environmental impact of the detergent composition. The composition is boron-free and compres (i) at least one anionic surfactant, preferably selected from the group of sulfonates, ether sulfates, and / or alkyl sulfates, and salts of fatty acids (soap), and combinations thereof, (ii) at least one alkanolamine, preferably ethanolamine, even more preferred monoethanolamine, (iii) at least 50 wt.% water, wherein said composition has a pH value in the range from 6 to 10, and wherein said composition comprises less than 0.05 wt.% of a total amount of conventional preservative(s) of the group comprising benzoic acid, benzoates, phenoxyethanol, sorbates, sulfites, phenoxyethanol, sodium or zinc pyrithione, bronopol, iodopropynylbutylcarbamate, formaldehyde and formaldehyde releaser, glyoxal, glutaral and isothiazolinones. The use of alkanolamines and of the combination of alkanolamines (ii) and anionic surfactant(s) (i) to reduce / inhibit microbial growth in aqueous systems, preferably in aqueous detergent compositions, more preferred in boron-free aqueous detergent compositions, which are free of any conventional preservative, is also disclosed.

The invention provides various salt forms of deuterated dextromethorphan as shown in a formula (I) as well as a preparation method and application of the various salt forms. The various salt forms comprise tartrate, citrate, hydrobromide and benzoate. Also provided are various crystal forms of the above salts. The salt has excellent effects in the aspects of stability, biological activity, bioavailability, drug effect and the like, and is suitable for development of pharmaceutical preparations.

The invention relates to the technical field of chemical pharmacy, and particularly discloses a preparation method of nafamostat mesylate. The preparation method comprises the following steps: adding 6-amidinyl-2-naphthol mesylate, 4-guanidinobenzoic acid hydrochloride and EDCI into a first solvent, and carrying out condensation reaction; adding a saturated sodium bicarbonate aqueous solution to obtain an intermediate; and adding the intermediate into a second solvent, adding methanesulfonic acid to form salt, and purifying to obtain the nafamostat mesylate. EDCI firstly reacts with a first solvent and is activated, nitrogen atoms with positive charges in EDCI after oxygen atoms on carbonyl carbon of carboxylic acid are activated are positively charged, the electrophilicity of carboxylic acid is increased, an active intermediate is formed, the active intermediate and alcohol are more easily subjected to nucleophilic substitution reaction, and dehydration condensation is performed to form an ester bond. EDCI is used as a condensing agent, so that the production efficiency and yield of the nafamostat mesylate are improved, the purity of the nafamostat mesylate is improved, the impurity content is reduced, the cost is low, and industrial production is easy.

Disclosed are salts of benzoic acid and prodrugs thereof for slowing the progression of or reducing the severity of a symptom associated with a nervous system injury in a subject.

To provide a crystal of 2 - (4-acetylbenzyl) - 3 - ((4-fluorophenyl) amino) - 577 - trimethyl-7, 8-dihydro-pyrazolo-imidazo [1, 2-a] 2H [4, 3-e] pyrimidin-4 (5H) - one.SOLUTION: Provided is a crystal of an acid addition salt form selected from, for example, succinate form, citrate form, adipate form, tartrate form (e.g., L-tartrate form), malate form, gluconate form (e.g., D-gluconate form), maleate form, fumarate form, aspartate form (e.g., L-aspartate form), hippurate form, sebacate form, glycolate form, galactarate form, benzoate form, pamoate form, oxalate form and malonate form.SELECTED DRAWING: None

Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and / or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography.

Provided are a salt and / or a crystal form of a compound degrading BTK and preparation and application thereof. The pharmaceutically acceptable salt and crystal form of the compound as shown in formula (I), wherein the pharmaceutically acceptable salt is selected from a maleate salt, a fumarate salt, a hydrogen halide salt (preferably a hydrobromide salt and a hydrochloride salt), a sulfate salt, a phosphate salt, an L-tartrate salt, a citrate salt, an L-malate salt, a hippurate salt, a D-glucuronate salt, a glycolate salt, a mucate salt, a succinate salt, a lactate salt, an orotate salt, a pamoate salt, a glycine salt, an alanine salt, an arginine salt, a cinnamate salt, a benzoate salt, a benzene sulfonate salt, a p-toluene sulfonate salt, an acetate salt, a propionate salt, a valerate salt, a triphenylacetic acid salt, an L-proline salt, a ferulic acid salt, a 2-hydroxyethanesulfonate salt, a mandelate salt, a nitrate salt, a methanesulfonate salt, a malonate salt, a gentisate salt, a salicylate salt, an oxalate salt or a glutarate salt:

A process for preparation of benzoate salt of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile, designated herein as Compound (A), and methods of using Compound (A) are provided. (I)

The invention features psilocin formulations for intravenous infusions including psilocin benzoate salt in combination with an antioxidant.

This invention relates to novel 2-(1-hydroxypentyl)benzoate, its preparation method, and its applications. Specifically, it relates to a cycloalkanamine 2-(1-hydroxypentyl)benzoate with the structure shown in Formula I, its preparation method, pharmaceutical compositions with the compound as the active ingredient, and the application of the compound in the treatment and / or prevention of ischemic cardiovascular and cerebrovascular diseases, especially mild, moderate, and severe acute ischemic stroke.

The present invention relates to the field of chemical pharmaceutical technology, and specifically discloses a preparation method of nafamostat mesylate. 6-amidino-2-naphthol mesylate, p-guanidinobenzoic acid hydrochloride and EDCI are added to a first solvent to carry out a condensation reaction; then a saturated sodium bicarbonate aqueous solution is added to obtain an intermediate; the intermediate is added to a second solvent, and then methanesulfonic acid is added to form a salt, and purified to obtain nafamostat mesylate. EDCI first reacts with the first solvent to be activated, and the oxygen atom on the carbonyl carbon of the carboxylic acid is positively charged in the activated EDCI, thereby increasing the electrophilicity of the carboxylic acid and forming an active intermediate, making it easier for it to undergo a nucleophilic substitution reaction with an alcohol, and undergoing dehydration condensation to form an ester bond. The present invention uses EDCI as a condensing agent, improves the production efficiency and yield of nafamostat mesylate, improves the purity of nafamostat mesylate, reduces the impurity content, and is low in cost and easy to industrialize.

The invention relates to a method for producing 4-cyanobenzoyl chloride of formula (I) from an alkali metal 4-carbamoyl-benzoate of formula (II) with a chlorinating agent and a catalyst. # imgabs0 #

The invention belongs to the technical field of agricultural biology, and particularly relates to application of ningnanmycin salt to prevention and treatment of tobacco mosaic virus diseases. Derivatives of ningnanmycin salts are developed on the basis of ningnanmycin, and the derivatives comprise ningnanmycin acetate, ningnanmycin lactate, ningnanmycin phosphate, ningnanmycin sulfate, ningnanmycin citrate, ningnanmycin benzoate, ningnanmycin oxalate, ningnanmycin hydrochloride, ningnanmycin nitrate and the like. When the ningnanmycin salts are applied to prevention and treatment of the tobacco mosaic viruses, experiments show that compared with ningnanmycin, the ningnanmycin salts have the advantages that the prevention and treatment effect on the tobacco mosaic viruses is remarkably improved, the prevention and treatment effect of moroxydine hydrochloride can be achieved or even exceeded, and the application prospect is good.

To provide a method for refining polypeptide including an Fc region.SOLUTION: A method includes the steps of: (a) bringing an affinity chromatography matrix in contact with a sample containing (i) polypeptide including an Fc region and (ii) one or more impurities under a condition that polypeptide including an Fc region bonds an affinity chromatography matrix; and (b) cleaning the matrix by a cleaning solution, in which the cleaning solution contains (i) benzoate having the concentration of approximately 0.1 M to approximately 1.0 M, (ii) benzyl alcohol having the concentration of approximately 0.5% to approximately 4% of volume / volume (v / v), and (iii) a buffer agent selected from the group consisting of phosphate, tris, arginine, acetate, citrate and carbonate, where the concentration of the buffer agent is approximately 10 mM to approximately 500 mM, and the cleaning solution has pH of approximately 4.0 to approximately 10.0.SELECTED DRAWING: Figure 1

The present invention relates to a hair care composition comprising from about 8 to about 17% of one or more surfactants; from about 0.01% to about 10% of one or more surfactant soluble anti-dandruff agents; from about 0.01% to about 5% of one or more thickening polymers based on polyacrylate or polyacrylamide; from about 0.02% to about 0.25% of a salicylate or acid; from about 0.02 to about 0.25% of a benzoate or acid, wherein there is a weight ratio of the salicylate or acid to the benzoate or acid of from about 1: 1 to 12.5: 1.

The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I) wherein: R1 each is independently F, Cl, Br, I, OCH3, CN or NO2; R2 each is independently identical or different C1-C5 alkyl; n1 is an integer between 1 and 5; and n2 is an integer between 1 and 4. In addition, the present invention provides a compound represented by the following structures: Compound (1a) and Compound (2), wherein X comprises: chloride, acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydroiodide, maleate, 2-hydroxyethanesulfonate, lactate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, sulfonate, tartrate, thiocyanate, toluenesulfonate, or undecanoate salt, or any combination thereof.

The present invention provides a plurality of salt forms of deuterated dextromethorphan represented by formula (I), a preparation method therefor and a use thereof. The deuterated dextromethorphan salt comprise tartrate, citrate, hydrobromate and benzoate. Also provided are a plurality of crystal forms of the salt. The salt exhibits excellent stability, bioactivity, bioavailability, medicinal effect and the like, and is suitable for development of pharmaceutical formulations.

The present invention provides an ester synthesized from a component A that is at least one selected from C2-8 divalent alcohols, a component B that is at least one selected from C2-10 divalent carboxylic acids, and a component C that is at least one selected from C4-6 hydroxycarboxylic acids having two or more carboxy groups.

This application discloses a traditional Chinese medicine oral ulcer patch containing camellia oil and its preparation method, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine oral ulcer patch containing camellia oil, by weight fraction, comprises: 7.1-9.1 parts camellia oil, 5-7 parts propolis, 2-4 parts Bletilla striata extract, 2-4 parts honeysuckle extract, 2-4 parts Artemisia argyi volatile oil, 4.4-6.4 parts collagen peptides, 14-16 parts polyvinyl alcohol, 4-6 parts hydroxypropyl methylcellulose, 4-6 parts glycerin, 1-3 parts polyethylene glycol, 0.2-0.4 parts benzoate, 0.1-0.3 parts menthol, and 0.5-1.5 parts vitamin E. This traditional Chinese medicine oral ulcer patch not only has anti-inflammatory effects, relieves oral ulcer pain, and promotes ulcer healing, but also forms a stable protective film layer in the oral cavity, effectively isolating external stimuli such as food friction and saliva erosion, providing a stable microenvironment for mucosal repair.

The present disclosure provides a method of preventing or treating cognitive dysfunction in a subject in need thereof, including administering to the subject an effective amount of a benzoic acid salt.